In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Marco Valgimigli
Speaker
Marco Valgimigli
Marco Valgimigli Marco Valgimigli

Cardiocentro Ticino Foundation, Lugano (Switzerland)

Speciality : Interventional Cardiology

Valgimigli’s research has influenced both European and USA clinical practice guidelines in multiple aspects. Impacting the coronary stent selection, regimens of various anti-thrombotic drugs & access site choice during coronary intervention. Initially starting as member/reviewer of multiple ESC guidelines task forces, he then acted as chair of the European update guidelines on DAPT. He acted as PI for multiple investigator initiated global randomized studies in interventional cardiology. Studies such as Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS) and the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) which comprised of 3 different randomization schemes in a quasi factorial study design. He conceived & designed both studies, identified the grant givers, overseeing the sponsor’s & clinical research organizations’ activities leading to the published results in multiple peer reviewed journals

27 presentations from this speaker

Shorter double antiplatelet treatment in acute coronary syndromes: for whom?

Event : ESC Congress 2020

  • Session : Hot Topics in Non-ST Elevation Acute Coronary Syndromes
  • Speaker : M Valgimigli (Lugano,CH)
  • Joint with the Argentine Society of Cardiology (ASC)

Bare metal stents vs drug-eluting stents.

Event : ESC Congress 2019

  • Session : The Lancet-ESC symposium on ischemic heart disease
  • Speaker : M Valgimigli (Lugano,CH)
  • Organised with The Lancet Journal

Discussant review - POPular Genetics

Event : ESC Congress 2019

  • Session : Hot Line Session 6
  • Speaker : M Valgimigli (Lugano,CH)

P2Y12 inhibition should be started at the time of NSTEMI diagnosis - PRO.

Event : ESC Congress 2019

  • Session : Controversies in anti-platelet therapy
  • Speaker : M Valgimigli (Lugano,CH)

State of the Art lecture: Prolonged DAPT – when, in whom, how long?

Event : Acute Cardiovascular Care 2019

  • Session : Prolonged DAPT after acute coronary syndrome: individualise!
  • Speaker : M Valgimigli (Lugano,CH)

The trial of the trial: Assessing GLOBAL LEADERS innovations, limitations and implications for clinical practice - Conclusion.

Event : Acute Cardiovascular Care 2019

  • Session : The trial of the trial: Assessing GLOBAL LEADERS innovations, limitations and implications for clinical practice
  • Speaker : M Valgimigli (Lugano,CH)

DAPT - Shorter is better

Event : ESC Congress 2018

  • Session : Dual antiplatelet therapy and PCI - Important controversies
  • Speaker : M Valgimigli (Lugano,CH)

DAPT - Shorter is better - Rebuttal.

Event : ESC Congress 2018

  • Session : Dual antiplatelet therapy and PCI - Important controversies
  • Speaker : M Valgimigli (Lugano,CH)

MATRIX trial - Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox

Event : ESC Congress 2018

  • Session : Late Breaking Science in Interventional Cardiology 1
  • Speaker : M Valgimigli (Lugano,CH)

Aspirin for life - CON

Event : ESC Congress 2017

  • Session : Aspirin for life
  • Speaker : M Valgimigli (Lugano,CH)

Aspirin for life - Rebuttal CON

Event : ESC Congress 2017

  • Session : Aspirin for life
  • Speaker : M Valgimigli (Lugano,CH)

Focused update on dual antiplatelet therapy

Event : ESC Congress 2017

  • Session : Meet the Guidelines task force - Focused update on dual antiplatelet therapy developed in collaboration with EACTS
  • Speaker : M Valgimigli (Lugano,CH)

Focused update on dual antiplatelet therapy developed in collaboration with EACTS

Event : ESC Congress 2017

  • Session : ESC Guidelines 2017 - Overview
  • Speaker : M Valgimigli (Lugano,CH)

A TAVI candidate with atrial fibrillation and high bleeding risk - Clinical case

Event : ESC Congress 2016

  • Session : Open issues in valvular heart disease
  • Speaker : M Valgimigli (Lugano,CH)

Reconciling the inconsistencies - State of the art

Event : ESC Congress 2016

  • Session : Tailoring dual anti platelet therapy to patient, procedure and stent
  • Speaker : M Valgimigli (Lugano,CH)

Invasive strategies and revascularisation.

Event : ESC Congress 2015

  • Session : ESC Guidelines - Acute Coronary Syndromes Non-ST-Elevation
  • Speaker : M Valgimigli (Lugano,CH)

Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX (MATRIX Antithrombin).

Event : ESC Congress 2015

  • Session : Press Conference - Hot Line VI - Coronary artery disease
  • Speaker : M Valgimigli (Lugano,CH)

Optimal DAPT duration after coronary stent implantation

Event : ESC Congress 2015

  • Session : Hot topics in interventional cardiology 2015
  • Speaker : M Valgimigli (Lugano,CH)

Coronary artery disease patients: take home messages.

Event : ESC Congress 2014

  • Session : Coronary artery disease patients: knife, needle or tablets?
  • Speaker : M Valgimigli (Lugano,CH)

Introduction to the session.

Event : ESC Congress 2014

  • Session : Coronary artery disease patients: knife, needle or tablets?
  • Speaker : M Valgimigli (Lugano,CH)

Technical considerations beyond platelet response in elective PCI.

Event : ESC Congress 2014

  • Session : Antiplatelet treatment in stable coronary artery disease patients
  • Speaker : M Valgimigli (Lugano,CH)

Two decades of controversy - The evolving story of GP Iib/IIIa treamtent.

Event : ESC Congress 2014

  • Session : Controversies in high-risk PCI - Future directions for early adjuvant therapies
  • Speaker : M Valgimigli (Lugano,CH)
  • Sponsored by Cardiome International AG

When to stop dual antiplatelet therapy after ACS – less is more?

Event : ESC Congress 2014

  • Session : Clinical challenges in ischaemic heart disease - best treatment options with difficult clinical case scenarios
  • Speaker : M Valgimigli (Lugano,CH)

Contra.

Event : ESC Congress 2013

  • Session : Platelet response testing should be abandoned.
  • Speaker : M Valgimigli (Lugano,CH)

Contra.

Event : ESC Congress 2013

  • Session : Platelet response testing should be abandoned.
  • Speaker : M Valgimigli (Lugano,CH)

What do the ESC and ACC/AHA guidelines on the use of oral antiplatelet therapies in the treatment of acute coronary syndromes tell us? Case study.

Event : ESC Congress 2013

  • Session : Cases on optimising oral antiplatelet therapy in the management of acute coronary syndromes
  • Speaker : M Valgimigli (Lugano,CH)
  • Sponsored by AstraZeneca

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are